HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.052373v1 49/10/1613    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ilias, I. Articles by Pacak, K. Search for Related Content PubMed PubMed Citation Articles by Ilias, I. Articles by Pacak, K.

Comparison of 6-¹⁸F-Fluorodopamine PET with ¹²³I-Metaiodobenzylguanidine and ¹¹¹In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma

¹ Reproductive Biology and Adult Endocrinology Program, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; ² Nuclear Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland; ³ Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Maryland; and ⁴ Department of Medicine, Faculty of Medicine, P.J. afárik University, Koice, Slovak Republic

Correspondence: For correspondence or reprints contact: Karel Pacak, Section on Medical Neuroendocrinology, Reproductive Biology and Adult Endocrinology Program, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, CRC, 1 East, Room 1-3140, 10 Center Dr., MSC-1109, Bethesda, MD 20892-1109. E-mail: karel{at}mail.nih.gov

We compared functional imaging modalities including PET with 6-¹⁸F-fluorodopamine (¹⁸F-DA) with ¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) and somatostatin receptor scintigraphy (SRS) with ¹¹¹In-pentetreotide in nonmetastatic and metastatic pheochromocytoma (PHEO). Methods: We studied 25 men and 28 women (mean age ± SD, 44.2 ± 14.2 y) with biochemically proven nonmetastatic (n = 17) or metastatic (n = 36) PHEO. Evaluation included anatomic imaging with CT or MRI and functional imaging that included at least 2 nuclear medicine modalities: ¹⁸F-DA PET, ¹²³I-MIBG scintigraphy, or SRS. Sensitivity of functional imaging versus anatomic imaging was assessed on a per-patient and a per-region basis. Results: For this available cohort, on a per-patient basis overall sensitivity (combined for nonmetastatic and metastatic PHEO) was 90.2% for ¹⁸F-DA PET, 76.0% for ¹²³I-MIBG scintigraphy, and 22.0% for SRS. On a per-region basis, overall sensitivity was 75.4% for ¹⁸F-DA PET, 63.4% for ¹²³I-MIBG scintigraphy, and 64.0% for SRS. Conclusion: If available, ¹⁸F-DA PET should be used in the evaluation of PHEO, because it is more sensitive than ¹²³I-MIBG scintigraphy or SRS. If ¹⁸F-DA PET is not available, ¹²³I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) and SRS (for metastatic PHEO) should be the first alternative imaging methods to be used.

Key Words: radionuclide imaging • ¹⁸F-fluorodopamine • ¹²³I-metaiodobenzylguanidine • ¹¹¹In-pentetreotide • pheochromocytoma

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				F. Imani, V. G. Agopian, M. S. Auerbach, M. A. Walter, F. Imani, M. R. Benz, R. A. Dumont, C. K. Lai, J. G. Czernin, and M. W. Yeh 18F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas J. Nucl. Med., April 1, 2009; 50(4): 513 - 519. [Abstract] [Full Text] [PDF]